Gut-Derived Ammonia Drives CD8 T-Cell–Mediated MASH : J Clin Invest | May 2026

Introduction

Metabolic Dysfunction-Associated Steatohepatitis is increasingly recognized as a multisystem disorder involving complex interactions between metabolism, intestinal microbiota, immune activation and fibrosis. Although gut dysbiosis has long been implicated in MASH progression, the precise microbial metabolites and immune pathways driving hepatic injury remain incompletely defined. This translational study investigated how ammonia-producing intestinal bacteria modulate hepatic immune injury and evaluated the therapeutic potential of the glycine-based tripeptide DT-109.

Problem Statement

The mechanisms linking intestinal microbial dysbiosis to hepatic immune-mediated injury in MASH remain poorly understood. In particular, whether gut-derived ammonia directly contributes to hepatic inflammation and cytotoxic immune activation beyond its established role in cirrhosis-associated encephalopathy has remained unclear.

Summary

Using integrated human, murine and non-human primate MASH models, this study identified a major expansion of the ammonia-producing bacterium Clostridium perfringens within the intestinal microbiome during MASH progression. Elevated intestinal ammonia levels were associated with impaired intestinal barrier integrity, increased systemic exposure to microbial products and heightened hepatic immune activation.

Mechanistically, gut-derived ammonia promoted FosB-dependent upregulation of chemokine CCL5 within hepatic CD8+ T cells, driving enhanced cytotoxic T-cell activity and liver injury. Functional experiments using microbiota transplantation and genetically modified ammonia-deficient C. perfringens mutants confirmed a causal relationship between bacterial ammonia production and MASH severity. The study therefore establishes ammonia not merely as a metabolic waste product but as an active immunomodulatory mediator within the gut–liver axis.

Therapeutically, DT-109 demonstrated significant efficacy across both murine and non-human primate models. Treatment reduced intestinal C. perfringens abundance, lowered ammonia production, restored intestinal barrier function and attenuated hepatic CD8+ T-cell dysregulation. These improvements translated into reduced steatohepatitis severity and amelioration of inflammatory liver injury. The findings suggest that modulation of microbial ammonia metabolism may represent a novel therapeutic strategy for MASH distinct from traditional metabolic-targeted approaches.

Overall, this study identifies a previously unrecognized microbiota–ammonia–CD8 T-cell axis contributing to MASH pathogenesis and positions DT-109 as a promising microbiome-directed immunometabolic therapy. The work further reinforces the emerging concept that intestinal microbial metabolites actively shape hepatic immune injury and may provide tractable therapeutic targets in progressive steatotic liver disease.